March 3, 2016 – As the FDA fails to update or further clarify its policy regarding off-label promotion, the courts continue to hear cases that are being decided in favor of allowing.S. District Judge Royce Lamberth has entered an order dismissing the case; it is not subject to appeal. companies to share truthful and non-misleading […]
Read moreTag: pitts
pittsIndustry More Than Ready for FDA Off-label Communications Guidance
Feb. 2, 2016 – The FDA’s recent announcement regarding which new and revised guidance documents it plans to publish in 2016 includes four long-awaited guidance documents by the Office of Prescription Drug Promotion (OPDP). “While the agency has been pondering its options, consumers and health professionals are expecting the industry to move forward and participate […]
Read moreCMPI: Value of Prescription Drugs Is Underestimated
Sept. 21, 2015 – Despite widespread reports about the soaring prices of prescription drugs and calls by the federal government and members of Congress to lower these prices and break patents, the Center for Medicine in the Public Interest (CMPI) contends that it is time for a “careful examination of the rest of the story” […]
Read morePitts Responds to New York Times Articles: DTC Ads Have No Impact on Drug Pricing
Oct. 17, 2013 – In his Drugwonks.com blog yesterday, Peter Pitts, President and Co-founder of the Center for Medicine in the Public Interest, said that the assertion in two recent articles in The New York Times that direct-to-consumer advertising is driving up drug prices is “not true.” An Oct. 15 Times article states: “Such advertising […]
Read morePitts Reminds Companies They Need To Be Careful With Sponsored Tweets
Sept. 9, 2013 – In a recent blog post on Drugwonks.com, entitled “Tweeter Reflux,” Peter Pitts reminded industry that although social media may pose complex questions, sponsored tweets are not that complicated. They are paid advertisements, pure and simple. Pitts cites AstraZeneca’s recent withdrawal of paid ads from the Associated Press’ Twitter feed because although […]
Read morePitts: FDA Needs to Address Guidance on Healthcare Economic Information
July 24, 2013 – In a recent blog post on DrugWonks.com, Center for Medicine in the Public Interest President and Co-founder Peter Pitts states that the FDA has indicated that it finally may be getting around to preparing a guidance document that describes the agency’s position on a provision (Sec. 114) of the FDA Modernization […]
Read morePitts: Important Details on Government Detailing
June 13, 2012 – In a recent blog entry on Drugwonks.com, Center for Medicine in the Public Interest President and Co-founder Peter Pitts provides a link to his article on government detailing in a recent issue of the Drug Information Journal (). In the article, Pitts states that this so-called “academic” detailing is important to […]
Read more